FY2022 Q3 Financial and R&D Update
Best percentage change in
SOD from baseline by BICR
Best percentage change in SOD
from baseline by BICR (n=39)*
Dato-DXd
100-
80-
60-
40
20
0
-20
-40.
-60
-80
-100-
100-
50
-50-
TROPION-PanTumor01 Study
SABCS 2022, HR positive and HER2 low or negative BC Cohort
Efficacy
Antitumor Responses by BICR (n=39)
a Postbaseline tumor assessments were not available for 1 patient at data cutoff.
One patient was not confirmed to have a target lesion per BICR and therefore had a best overall response of non-CR/non-PD.
Ongoing
-100-
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
Time, weeks
Data Cutoff: July 22, 2022
TROPION-PanTumor01
Daiichi-Sankyo
HR positive and HER2 low or negative BC
Cohort
Cohort of patients with HR positive and HER2 low or
negative unresectable or metastatic BC in Ph1 trial to:
evaluate safety and efficacy of Dato-DXd
■Dato-DXd showed encouraging and durable efficacy in
patients with HR positive and HER2 low or negative BC
who previously received median of 5 lines of treatment
for metastatic disease
•
•
Confirmed ORR and DCR were 27% and 85%,
respectively
mPFS was 8.3 months
95% patients were pretreated with CDK4/6
inhibitors
Dato-DXd demonstrated a manageable safety profile
with no new safety signals. The most common TEAEs
were stomatitis, nausea, and fatigue
Durable efficacy and manageable safety shown in TROPION-Pan Tumor01
raises confidence in TROPION-Breast01 study
BC: breast cancer, BICR: blinded independent central review, DCR: disease control rate, HR: hormone receptor, mPFS: median progression-free survival, ORR: objective response rate, SABCS: San Antonio Breast Cancer Symposium, 23
TEAEs: treatment emergent adverse eventsView entire presentation